Observational studyEuropean journal of medical research2025
The association of the metabolic score for insulin resistance and metabolic dysfunction-related steatosis liver disease: a population-based observational study.
Observational study in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Determinants of Metabolic Dysfunction-Associated Steatotic Liver Diseases in Patients with Type 2 Diabetes Mellitus.Journal of clinical medicine · 2026Article
- Explainable Clinical Decision Support for Metabolic Index Prediction in Gout Patients Using GA-Optimized Ensemble Learning Models.Diagnostics (Basel, Switzerland) · 2026Article
- Non-linear association between metabolic score for insulin resistance and diabetes mellitus in normal-weight middle-aged and older Chinese adults: a multicenter retrospective cohort study.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundInsulin resistance (IR) plays a pivotal role in the pathogenesis and advancement of metabolic dysfunction-related steatosis liver disease (MASLD). Despite the recent proposal of the metabolic score for insulin resistance (METS-IR) as a dependable indirect indicator of IR, limited research has delved into the correlation between METS-IR and MASLD risk. Consequently, the objective of this study was to examine the relationship between METS-IR and MASLD within the U.S. population and evaluate its predictive capacity for MASLD risk.
methodsBased on data from the National Health and Nutrition Examination Survey (NHANES), a cross-sectional study was carried out on 2764 participants. The laboratory measurements and clinical data, which are risk factors for MASLD, were analyzed.
resultsAfter adjustment for confounders, a significant, stable, and positive association was demonstrated between METS-IR and MASLD risk (Odds ratio (OR) increase of 2.28 per standard deviation (SD)), 95% confidence interval (CI) 1.58 to 3.30, P for trend = 0.001). Consistently, the area under the receiver operating characteristic curve (AUC) showed that METS-IR (AUC (95% CI) 0.823 (0.807-0.838)) better predicted the risk of MASLD than homeostasis model assessment (HOMA-IR), triglyceride glucose index (TyG), triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL), visceral adiposity index (VAI), and hepatic steatosis index (HSI). Not only that, the AUC of METS-IR on the risk of MASLD remained the greatest in the subgroups of sex, age, race, overweight status, hypertension status, and diabetes status. Furthermore, integrated discrimination improvement (IDI), decision curve analysis (DCA), and net reclassification index (NRI) also showed satisfactory predictive power of METS-IR.
conclusionsIn this dataset, METS-IR was found to be linked to an increased risk of MASLD and can be a useful tool for identifying individuals at high risk of MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.